How does startup funding work?

Startup funding is the process of raising money to move your product from an idea to a real business. In medtech, it’s less about “growth at all costs” and more about risk reduction: each round of funding is meant to pay for specific milestones that make the company meaningfully less risky (technical, clinical, regulatory, reimbursement, and go-to-market).

Most first-time clinician/engineer founders get tripped up because they assume funding is a single event (“we raise money”), when it’s actually a sequence of decisions: what type of capital (non-dilutive vs equity vs debt), how much, at what valuation, and for which milestones. Investors don’t fund “ideas”; they fund a plan to hit the next proof point.

1) The core mechanics: dilution, valuation, and runway

Three concepts explain 80% of how startup funding works:

• Valuation: what the company is “worth” for the purpose of the financing. In early stages this is negotiated, not calculated like a public stock.
• Dilution: when you sell equity, your ownership percentage goes down. Example: if you own 100% and sell 20% to investors, you now own 80% (before option pools and future rounds).
• Runway: how long your cash lasts. A simple formula is runway (months) = cash / monthly burn. “Burn” is net cash outflow per month.

Medtech-specific nuance: your burn is often milestone-driven (prototype builds, verification/validation, quality system work, clinical studies, regulatory submissions). That means you should plan funding around milestone budgets, not just “12–18 months of runway.”

Also expect an option pool (equity reserved for hires). Investors often ask you to create/expand it before the round closes, which effectively increases dilution to founders.

2) The medtech funding ladder (and what each stage pays for)

Medtech companies typically stack multiple funding types over time. Here’s a practical map of what “good use of funds” looks like at each stage.

Bootstrapping + non-dilutive (earliest stage)

Bootstrapping means using your own cash or revenue to fund progress. Non-dilutive funding means you don’t give up equity (e.g., grants, some innovation challenges, paid pilots, research contracts). In medtech, non-dilutive can be powerful because it buys time to de-risk without giving away ownership too early.

Typical milestones to fund here:

• Clear problem definition and clinical workflow mapping (who uses it, when, and why).
• Early prototype and feasibility testing.
• Initial regulatory pathway hypothesis: 510(k) vs De Novo vs PMA (and why).
• Early reimbursement thinking: existing CPT codes vs new code pathway (if relevant).

Pre-seed / Seed (first institutional money)

Seed investors (angels, seed funds) usually fund you to prove you can build and validate a product and that there’s a credible path to clearance and adoption. In medtech, “validation” often includes more than a demo: it includes quality, clinical evidence planning, and stakeholder buy-in.

Common seed-funded deliverables:

• Design controls and a basic quality management system (QMS) appropriate to your device/software.
• Verification/validation planning; usability/human factors plan where applicable.
• Regulatory strategy refined with predicate analysis (for 510(k)) or De Novo rationale.
• Clinical study plan; if you need a study, you may need IRB approval and a site.
• Early commercial proof: LOIs, pilots, or paid evaluations (careful: hospitals can be slow).

Series A (scaling evidence + regulatory execution)

Series A in medtech is often about converting “promising” into “inevitable”: executing the regulatory plan, generating credible clinical evidence, and building a repeatable go-to-market motion.

Series A money commonly goes to:

• Regulatory submission execution (510(k), De Novo, or PMA depending on risk class and novelty).
• Clinical studies (feasibility and/or pivotal, depending on pathway and claims).
• Manufacturing scale-up planning (design transfer, suppliers, QA).
• Commercial groundwork: pricing, contracting, and early sales hires.

Series B+ (commercial scale)

Later rounds are usually about scaling sales, expanding indications, and building a durable business. For digital health, this can mean expanding integrations and distribution; for devices, it can mean expanding the sales force, distributor relationships, and manufacturing capacity.

3) Medtech investors underwrite three risks: FDA, reimbursement, and procurement

In software startups, investors often focus on product-market fit and growth. In medtech, you must also show you can navigate three institutional gates:

Regulatory: 510(k) vs De Novo vs PMA

Investors want a defensible pathway and a timeline that matches your capital plan.

• 510(k): you show “substantial equivalence” to a predicate device. Investors will ask: what’s the predicate, what are the differences, and do those differences trigger new clinical data needs?
• De Novo: for novel, low-to-moderate risk devices without a predicate. Investors will ask: what evidence is needed to establish safety/effectiveness and create a new classification?
• PMA: for higher-risk devices; typically more evidence-heavy. Investors will ask: can this team raise enough capital and run the studies required?

Key point: funding rounds should align to regulatory inflection points (e.g., pre-submission feedback, submission filed, clearance/approval).

Reimbursement: who pays and under what code?

A product can be clinically valuable and still fail commercially if nobody gets paid. Investors will pressure-test:

• Is there an existing CPT code (or DRG/HCPCS as relevant) that supports payment?
• If not, what’s the plan—new code, coverage strategy, or a budget-neutral value story?
• Does the economic buyer (hospital, payer, employer) capture the value you create?

If reimbursement is unclear, you may still raise money, but you’ll likely be forced into narrower claims, specific customer segments, or alternative pricing models until reimbursement is solved.

Hospital procurement: selling is a process, not a pitch

Hospitals buy through committees and workflows: clinical champions, value analysis committees, IT/security reviews (for digital), supply chain, and sometimes GPO dynamics. Investors want evidence you can get through procurement, not just clinician enthusiasm.

Strong proof points include: a pilot with defined success metrics, a path to conversion, and a realistic sales cycle assumption (which varies widely by product and hospital type).

4) Common funding instruments (what you’ll actually sign)

Funding is not just “money in the bank.” It’s a legal instrument with specific tradeoffs.

Equity priced rounds

A priced round sells shares at a negotiated valuation. Pros: clarity. Cons: more legal work and valuation negotiation early.

Convertible notes and SAFEs

These are common at pre-seed/seed. They convert into equity later, usually with a valuation cap (max conversion valuation) and/or a discount to the next round’s price. They’re faster, but founders often underestimate how multiple notes/SAFEs stack and affect dilution.

Venture debt (later, with traction)

Debt can extend runway without immediate dilution, but it adds repayment obligations and covenants. In medtech, lenders often want strong investors, revenue visibility, or clear regulatory progress.

5) What investors expect in a medtech fundraise (your “proof package”)

To raise efficiently, you need a coherent story backed by evidence. A practical checklist:

1. Clinical problem + user: who uses it, what decision it changes, and why current workflow fails.
2. Regulatory plan: pathway (510(k)/De Novo/PMA), key risks, and what data you need.
3. Evidence plan: endpoints, study design concept, IRB needs, and timeline assumptions (high level).
4. Reimbursement + pricing logic: who pays, why they pay, and how pricing ties to value.
5. Go-to-market: target customer (IDNs, community hospitals, clinics), sales motion, and procurement path.
6. Milestone-based use of funds: “We are raising X to achieve Y by date Z,” where Y is a de-risking milestone (not vague “growth”).

If you’re a clinician-founder, your credibility is a strength—but investors still need to see that you can build a business system: quality, regulatory, reimbursement, and sales execution.

What to do next

1. Write a milestone-based raise plan: list the next 3–5 de-risking milestones (regulatory, clinical, reimbursement, procurement) and estimate the budget for each.
2. Pressure-test your FDA pathway: document why you believe it’s 510(k), De Novo, or PMA and what evidence is likely required; update after expert feedback.
3. Map the economic buyer: identify who signs, who influences, and what budget it comes from (department, capital, operating, IT). Turn this into a one-page procurement path.
4. Build your investor narrative: a tight deck that connects problem → product → evidence → regulatory → reimbursement → sales, with a clear “use of funds.”